Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IIQ.AX
Strong SellINOVIQ Ltd · Healthcare · Australia · $53M · Avg Vol: $11K/d
12
StockRankGet insider-trade alerts
Q
34
V
34
M
20
P/E (TTM)
—
ROE
-34.7%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.
FINANCIAL SUMMARY (AUD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.3M | 0.4M | 0.5M | — | 39.1% | 2.1M | 0.9M | 1.4M | 37.8% |
| EPS (AUD) | -0.07 | -0.10 | -0.07 | -0.06 | — | -0.06 | -0.04 | -0.04 | — |
| Shares | 92.0M | 92.0M | 105.5M | — | +14.7% | 140.8M | — | — | — |
| Debt | 1.0M | 0.7M | 0.4M | — | -36.4% | 0.3M | — | — | — |
| Equity | 28.3M | 19.6M | 20.0M | — | -16.0% | — | — | — | — |
| Op CF | -6.1M | -7.0M | -4.3M | — | — | -5.0M | — | — | — |
| Inv CF | -0.4M | -0.3M | -0.2M | — | — | — | — | — | — |
| Fin CF | 16.9M | -0.3M | 5.9M | — | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-12.5%
SMA 50SMA 200
Close
$0.1254
RSI (14)
30.8
52W High
$0.4048
From 52W High
0.3%
SCORE BREAKDOWN
Quality
34
ROIC (ROA)
-20.7%*30.2
ROE
-34.7%24.8
GP/Assets
-10.0%6.8
Op. Margin
-370.0%11.7
FCF/Assets
-13.3%27.3
Piotroski
550.3
Int. Cover
—N/A
D/E Ratio
0.01x83.4
Current Ratio
7.56x81.3
Value
34
P/E (TTM)
—N/A
EV/EBITDA
-1.5x25.0
P/FCF
—N/A
P/B
1.1x82.2
P/S
11.4x25.0
Div Yield
—N/A
Momentum
20
52W High %
31%7.9
RS 6M
-45%17.5
SMA 50/200
0.78x16.1
EPS Rev 4W
-4.1%16.6
EPS Rev 12W
—N/A
EPS Improve
+33%45.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$53M
P/E (Forward)
-4.3x
Gross Margin
-99.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IIQ.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IIQ.AX | INOVIQ Ltd(you) | $53M | 12 | Strong Sell |
| HLS.AX | Healius Limited | $226M | 39 | Hold |
| MVF.AX | Monash IVF Group Limited | $190M | 56 | Hold |
| ALA.AX | Arovella Therapeutics Limited | $53M | 14 | Strong Sell |
| IMM.AX | Immutep Limited | $53M | 9 | Strong Sell |
| BOT.AX | Botanix Pharmaceuticals Limited | $51M | 9 | Strong Sell |
| COV.AX | Cleo Diagnostics Ltd | $54M | 6 | Strong Sell |
| PKY.AX | Pathkey.AI Ltd | $57M | 21 | Sell |
| PTX.AX | Prescient Therapeutics Limited | $50M | 22 | Sell |
| PHX.AX | PharmX Technologies Limited | $59M | 22 | Sell |
Peer medians: ROE -20.6% · P/E 34.6x · Gross margin 62.6%